These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 24462139)

  • 1. Clinical outcomes with 6 months dual antiplatelet therapy after implantation of biolimus-A9 drug eluting coronary stents.
    Cockburn J; Pareek N; Poliacikova P; Saraf S; Williams R; Dhillon G; Robinson D; Gerber R; Hatrick R; Blows L; de Belder A; Hildick-Smith D
    Int J Cardiol; 2014 Mar; 172(1):185-9. PubMed ID: 24462139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry.
    Urban P; Valdés M; Menown I; Eberli F; Alhaddad I; Hildick-Smith D; Iosseliani D; Roffi M; Oldroyd K; Kalloudi E; Eerdmans P; Berland J; Kleber FX;
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1151-60. PubMed ID: 25683225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials.
    de Waha A; Stefanini GG; King LA; Byrne RA; Serruys PW; Kufner S; Meier B; Jüni P; Kastrati A; Windecker S
    Int J Cardiol; 2013 Oct; 168(6):5162-6. PubMed ID: 23993323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
    Christiansen EH; Jensen LO; Thayssen P; Tilsted HH; Krusell LR; Hansen KN; Kaltoft A; Maeng M; Kristensen SD; Bøtker HE; Terkelsen CJ; Villadsen AB; Ravkilde J; Aarøe J; Madsen M; Thuesen L; Lassen JF;
    Lancet; 2013 Feb; 381(9867):661-9. PubMed ID: 23374649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
    Klauss V; Serruys PW; Pilgrim T; Buszman P; Linke A; Ischinger T; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; van Geuns RJ; van Es GA; Kalesan B; Wenaweser P; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2011 Aug; 4(8):887-95. PubMed ID: 21851904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
    Smits PC; Hofma S; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; Vuillomenet A; Serra A; Nouche RT; den Heijer P; van der Ent M
    Lancet; 2013 Feb; 381(9867):651-60. PubMed ID: 23374650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).
    Wykrzykowska J; Serruys P; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; Di Mario C; Van Geuns RJ; Van Es GA; Juni P; Windecker S
    EuroIntervention; 2011 Nov; 7(7):789-95. PubMed ID: 22027687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer-coated sirolimus-eluting coronary stents: Insight from the I-LOVE-IT 2 trial.
    Qi J; Li Y; Li J; Jing Q; Xu K; Gao C; Ma L; Zhang Z; Xu B; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):555-564. PubMed ID: 28318138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-month outcomes of patients unsuitable for prolonged DAPT presenting with an acute coronary syndrome and treated with polymer-free biolimus A9 drug-coated stents.
    Kinnaird T; Abdul F; Hailan A; Sheikh A; Hinton J; Yazji K; Elangovan S; Yousef A; Gallagher S; Choudhury A; Anderson R; O'Kane P; Smith D
    Catheter Cardiovasc Interv; 2018 Dec; 92(7):1220-1228. PubMed ID: 30244504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
    Han Y; Jing Q; Xu B; Yang L; Liu H; Shang X; Jiang T; Li Z; Zhang H; Li H; Qiu J; Liu Y; Li Y; Chen X; Gao R;
    JACC Cardiovasc Interv; 2009 Apr; 2(4):303-9. PubMed ID: 19463441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.
    Naidu SS; Krucoff MW; Rutledge DR; Mao VW; Zhao W; Zheng Q; Wilburn O; Sudhir K; Simonton C; Hermiller JB
    JACC Cardiovasc Interv; 2012 Jun; 5(6):626-35. PubMed ID: 22721657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
    Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial.
    Windecker S; Serruys PW; Wandel S; Buszman P; Trznadel S; Linke A; Lenk K; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; Davies S; van Geuns RJ; Eerdmans P; van Es GA; Meier B; Jüni P
    Lancet; 2008 Sep; 372(9644):1163-73. PubMed ID: 18765162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial.
    Kaiser C; Galatius S; Jeger R; Gilgen N; Skov Jensen J; Naber C; Alber H; Wanitschek M; Eberli F; Kurz DJ; Pedrazzini G; Moccetti T; Rickli H; Weilenmann D; Vuillomenet A; Steiner M; Von Felten S; Vogt DR; Wadt Hansen K; Rickenbacher P; Conen D; Müller C; Buser P; Hoffmann A; Pfisterer M;
    Circulation; 2015 Jan; 131(1):74-81. PubMed ID: 25411159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial.
    Wijns W; Steg PG; Mauri L; Kurowski V; Parikh K; Gao R; Bode C; Greenwood JP; Lipsic E; Alamgir F; Rademaker-Havinga T; Boersma E; Radke P; van Leeuwen F; Camenzind E;
    Eur Heart J; 2014 Oct; 35(40):2812-20. PubMed ID: 25106761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.